Nectar Lifescience Reports Significant Decline in Financial Performance for August 2025

Nectar Lifescience, a microcap company in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending June 2025 on August 14, 2025. The company has experienced notable challenges in its financial performance during this period. The net sales for the quarter stood at Rs 280.68 crore, reflecting a significant decline compared to the average net sales of Rs 418.27 crore over the previous four quarters. This marks the lowest sales figure recorded in the last five quarters, indicating a concerning trend in near-term sales performance. Additionally, the Profit Before Tax (PBT) for the quarter was reported at Rs -97.10 crore, which represents a substantial shift from the average PBT of Rs -40.86 crore in the prior four quarters. Similarly, the Profit After Tax (PAT) was recorded at Rs -63.23 crore, a notable change from the average PAT of Rs -28.42 crore over the same period. In light of these results, Nectar Lifescience has undergone an adjustment in its evaluation, with its score moving to -12 from -14 in the last three months. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.